Pfizer’s Vydura (rimegepant) Receives NICE Recommendation for Acute Treatment of Migraine
- The NICE has published a final draft guidance recommending Pfizer's Vydura (rimegepant) for use on the NHS as a cost-effective option for the acute treatment of migraine in adults who do not respond to two previous migraine medicines, called triptans. The final recommendations on rimegepant are expected in Oct 2023
- Additionally, the clinical results showed that rimegepant is more likely to reduce pain at 2hr. than a dummy drug
- Vydura was approved in the EU for the treatment and prevention of acute migraine attacks in 2022 & was also approved for both indications in the US and marketed as the drug Nurtec
Ref: Nice | Image: Pfizer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.